PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemi
AbstractCancers can be recognized by the immune system, and the immune system may regulate and even ...
Sézary syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphoma (L-CTCL) that ar...
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has yielded great ...
contributed equally to first or last authorship Running title: PD-L1 blockade re-activates anti-CLL...
International audienceThe co-inhibitory receptor programmed cell death (PD)-1, expressed by immune e...
BACKGROUNDPD-1 and PD-L1 have been studied interchangeably in the clinic as checkpoints to reinvigor...
PhDChronic lymphocytic leukaemia (CLL) is the most common adult leukaemia, and despite recent introd...
PD-1–PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-PD-1/PD-L1...
Immunotherapy with the programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) blockade has revol...
In tumor microenvironment, the programmed death 1 (PD-1) immune checkpoint has a crucial role of mec...
Chronic lymphocytic leukemia is marked by profound defects in T-cell function. Programmed death-1 is...
Chronic lymphocytic leukemia is marked by profound defects in T-cell function. Programmed death-1 is...
Abstract Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the...
The reinvigoration of anti-cancer immunity by immune checkpoint therapies has greatly improved cance...
The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the pr...
AbstractCancers can be recognized by the immune system, and the immune system may regulate and even ...
Sézary syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphoma (L-CTCL) that ar...
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has yielded great ...
contributed equally to first or last authorship Running title: PD-L1 blockade re-activates anti-CLL...
International audienceThe co-inhibitory receptor programmed cell death (PD)-1, expressed by immune e...
BACKGROUNDPD-1 and PD-L1 have been studied interchangeably in the clinic as checkpoints to reinvigor...
PhDChronic lymphocytic leukaemia (CLL) is the most common adult leukaemia, and despite recent introd...
PD-1–PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-PD-1/PD-L1...
Immunotherapy with the programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) blockade has revol...
In tumor microenvironment, the programmed death 1 (PD-1) immune checkpoint has a crucial role of mec...
Chronic lymphocytic leukemia is marked by profound defects in T-cell function. Programmed death-1 is...
Chronic lymphocytic leukemia is marked by profound defects in T-cell function. Programmed death-1 is...
Abstract Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the...
The reinvigoration of anti-cancer immunity by immune checkpoint therapies has greatly improved cance...
The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the pr...
AbstractCancers can be recognized by the immune system, and the immune system may regulate and even ...
Sézary syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphoma (L-CTCL) that ar...
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has yielded great ...